The data suggest that the determination of GP88 tumor expression at time of diagnosis for early stage breast cancer patients could provide additional survival information to that provided by NPI alone and thus may be useful for risk management of patients diagnosed with breast cancer. The gene discussed is GRN; the disease is breast cancer.